BRAVIFO INJECTION

Indications

• Breast cancer
• Ovarian cancer
• Non-small cell lung cancer
• Kaposi's sarcoma
• Pancreatic cancer
• Esophageal cancer

Dosage

Adults: The dosage of

Mechanism of action

Paclitaxel exerts its anticancer effects by binding to the beta subunit of the tubulin protein, which is a critical component of microtubules. This binding stabilizes the microtubule structure and prevents the normal depolymerization process, thereby disrupting the mitotic spindle formation during cell division. Consequently, this leads to cell cycle arrest in the G2/M phase and ultimately results in apoptosis of cancer cells.

Pharmacodynamics

Paclitaxel exhibits a cytotoxic effect on rapidly dividing cells, which is characteristic of many cancer cells. Its ability to stabilize microtubules results in a failure of cell division, leading to increased cell death. The drug has a broad spectrum of activity against various solid tumors, with its efficacy being influenced by factors such as the type of cancer, the presence of drug resistance mechanisms, and the overall health of the patient.

Pharmacokinetics

Paclitaxel is administered intravenously and is extensively distributed in the body, with a volume of distribution ranging from 50 to 150 L/m². It is highly bound to plasma proteins, predominantly albumin, with a protein binding percentage of approximately 90-95%. The metabolism of paclitaxel occurs primarily in the liver via cytochrome P450 enzymes, specifically CYP2C8 and CYP3A4, leading to the formation of inactive metabolites. The elimination half-life of paclitaxel typically ranges from 11 to 50 hours, and it is excreted mainly via the feces. Renal clearance is not significant, as less than 5% of the drug is excreted unchanged in urine.

Contra-indications

• Hypersensitivity to paclitaxel or any component of the formulation
• Severe bone marrow suppression
• Pregnancy

Adverse effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Peripheral neuropathy
• Alopecia
• Nausea and vomiting
• Diarrhea
• Mucositis
• Hypersensitivity reactions (including anaphylaxis)
• Cardiotoxicity (bradycardia, arrhythmias)
• Fatigue

Interactions

• CYP2C8 and CYP3A4 inhibitors (may increase paclitaxel levels)
• CYP2C8 and CYP3A4 inducers (may decrease paclitaxel levels)
• Other myelosuppressive agents (increased risk of hematologic toxicity)
• Live vaccines (immunosuppression may reduce vaccine effectiveness)

Precautions

• Monitor complete blood counts regularly due to risk of myelosuppression
• Exercise caution in patients with hepatic impairment
• Use with caution in patients with cardiovascular disease
• Pregnancy category D, use only if the potential benefit justifies the risk

Pregnancy

Paclitaxel is classified as a pregnancy category D drug. It is contraindicated in pregnancy due to potential harm to the fetus.

Breast-feeding

It is not known whether paclitaxel is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store at room temperature, protected from light. Do not freeze. Keep out of reach of children.

Formulations

• Injectable solution (various concentrations)
• Oral capsule (less common)